Stressgen sells reagents business, withdraws offering

Guest Contributor
May 3, 2005

Victoria-based Stressgen Biotechnologies Corp has withdrawn its proposed common shares offering, sold off its bioreagents business and replaced its president and CEO. The reagents business was sold for $8 million to the newly formed Stressgen Bioreagents Corp funded by Ampersand Ventures. Accompanying the sale are 26 of the firm’s 103 employees. The withdrawal of the February 25/05 share offering was blamed on unfavorurable market conditions and the firm’s current valuation. Several strategies are being pursued to preserve cash and seek co-funding for development of its fusion therapeutic vaccine technologies....


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.